CN106164289A - 癌症对免疫疗法的反应的决定因素 - Google Patents

癌症对免疫疗法的反应的决定因素 Download PDF

Info

Publication number
CN106164289A
CN106164289A CN201480075287.2A CN201480075287A CN106164289A CN 106164289 A CN106164289 A CN 106164289A CN 201480075287 A CN201480075287 A CN 201480075287A CN 106164289 A CN106164289 A CN 106164289A
Authority
CN
China
Prior art keywords
cancer
methods
cell
experimenter
test point
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480075287.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·常
J·沃尔乔克
A·斯尼德查伦
V·马卡罗维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN106164289A publication Critical patent/CN106164289A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480075287.2A 2014-01-02 2014-12-23 癌症对免疫疗法的反应的决定因素 Pending CN106164289A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461923183P 2014-01-02 2014-01-02
US61/923,183 2014-01-02
US201462066034P 2014-10-20 2014-10-20
US62/066,034 2014-10-20
US201462072893P 2014-10-30 2014-10-30
US62/072,893 2014-10-30
PCT/US2014/072125 WO2015103037A2 (en) 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy

Publications (1)

Publication Number Publication Date
CN106164289A true CN106164289A (zh) 2016-11-23

Family

ID=53494217

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480075287.2A Pending CN106164289A (zh) 2014-01-02 2014-12-23 癌症对免疫疗法的反应的决定因素

Country Status (15)

Country Link
US (1) US20160326597A1 (https=)
EP (1) EP3090066A4 (https=)
JP (1) JP2017504324A (https=)
KR (1) KR20160102314A (https=)
CN (1) CN106164289A (https=)
AU (1) AU2014374020A1 (https=)
BR (1) BR112016015399A2 (https=)
CA (1) CA2935214A1 (https=)
CL (1) CL2016001708A1 (https=)
MX (1) MX2016008771A (https=)
PE (1) PE20161344A1 (https=)
PH (1) PH12016501329A1 (https=)
RU (1) RU2707530C2 (https=)
SG (2) SG11201605432RA (https=)
WO (1) WO2015103037A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110295218A (zh) * 2018-03-22 2019-10-01 长庚医疗财团法人嘉义长庚纪念医院 量化靶基因的突变型等位基因负担的方法
CN110770838A (zh) * 2017-12-01 2020-02-07 Illumina公司 用于确定体细胞突变克隆性的方法和系统
CN110997943A (zh) * 2017-07-05 2020-04-10 弗朗西斯.克里克研究所 评估癌症免疫疗法的适合性的方法
CN111088349A (zh) * 2020-02-14 2020-05-01 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
CN111432837A (zh) * 2017-09-25 2020-07-17 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法
CN111566484A (zh) * 2017-11-09 2020-08-21 宾夕法尼亚大学董事会 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
CN112424382A (zh) * 2019-04-05 2021-02-26 Illumina公司 Hla多样性的定量评分
CN114245874A (zh) * 2019-05-24 2022-03-25 艾迪菲斯健康有限公司 用于癌症免疫疗法的精准医学方法
CN115667550A (zh) * 2020-03-23 2023-01-31 皇家飞利浦有限公司 基于免疫检查点基因对前列腺癌对象的放疗反应的预测

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP4098278A1 (en) 2014-11-13 2022-12-07 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
US10339274B2 (en) * 2015-10-12 2019-07-02 Nantomics, Llc Viral neoepitopes and uses thereof
EP3365000B1 (en) * 2015-10-23 2020-06-10 Novartis AG Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
US11585805B2 (en) 2016-02-19 2023-02-21 Nantcell, Inc. Methods of immunogenic modulation
CA3015913A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
EP3431595A4 (en) * 2016-03-15 2019-11-20 Repertoire Genesis Incorporation MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
DK3429618T5 (da) * 2016-03-16 2024-09-16 Amal Therapeutics Sa Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin
SG11201810951RA (en) * 2016-06-10 2019-01-30 Io Therapeutics Inc Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy
DK3515476T3 (da) 2016-09-21 2024-09-02 Amal Therapeutics Sa Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
AU2017339517B2 (en) * 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
CA3045811A1 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
US11480572B2 (en) 2016-12-16 2022-10-25 Nantbio, Inc. Live cell imaging systems and methods to validate triggering of immune response
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018146128A1 (en) * 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
US20200102618A1 (en) * 2017-03-17 2020-04-02 Nantomics, Llc LIQUID BIOPSY FOR cfRNA
KR102775647B1 (ko) * 2017-03-31 2025-03-06 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
EP3879535B1 (en) * 2017-06-13 2024-12-11 BostonGene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
MX2020003204A (es) 2017-09-20 2020-07-20 Regeneron Pharma Metodos de inmunoterapia para pacientes cuyos tumores portan una carga mutacional alta de un gen pasajero.
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CN108009400B (zh) * 2018-01-11 2018-07-06 至本医疗科技（上海）有限公司 全基因组肿瘤突变负荷预测方法、设备以及存储介质
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
JP7466519B2 (ja) 2018-07-23 2024-04-12 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
CN109371005B (zh) * 2018-11-12 2022-09-30 上海市东方医院（同济大学附属东方医院） 一种hla-0201限制性padi4表位多肽及其应用
CN113194995A (zh) * 2018-12-12 2021-07-30 免疫医疗有限责任公司 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
US20220081723A1 (en) * 2018-12-21 2022-03-17 Agency For Science, Technology And Research Method of predicting for benefit from immune checkpoint inhibition therapy
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
NL2024107B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
WO2022217136A1 (en) * 2021-04-10 2022-10-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A multiomic approach to modeling of gene regulatory networks in multiple myeloma
JP2024534120A (ja) 2021-08-24 2024-09-18 ビオンテック・ソシエタス・エウロパエア インビトロ転写技術
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4695807A1 (en) 2023-04-12 2026-02-18 Icahn School of Medicine at Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190149A1 (en) * 2001-12-04 2011-08-04 Michael Tainsky Neoepitope detection of disease using protein arrays
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
CN103180730A (zh) * 2010-05-14 2013-06-26 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
AU2005302459A1 (en) * 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190149A1 (en) * 2001-12-04 2011-08-04 Michael Tainsky Neoepitope detection of disease using protein arrays
CN103180730A (zh) * 2010-05-14 2013-06-26 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997943A (zh) * 2017-07-05 2020-04-10 弗朗西斯.克里克研究所 评估癌症免疫疗法的适合性的方法
CN111432837A (zh) * 2017-09-25 2020-07-17 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法
CN111566484A (zh) * 2017-11-09 2020-08-21 宾夕法尼亚大学董事会 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
CN110770838A (zh) * 2017-12-01 2020-02-07 Illumina公司 用于确定体细胞突变克隆性的方法和系统
US12367978B2 (en) 2017-12-01 2025-07-22 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN110770838B (zh) * 2017-12-01 2023-12-19 Illumina公司 用于确定体细胞突变克隆性的方法和系统
CN110295218B (zh) * 2018-03-22 2023-09-01 长庚医疗财团法人嘉义长庚纪念医院 量化靶基因的突变型等位基因负担的方法
CN110295218A (zh) * 2018-03-22 2019-10-01 长庚医疗财团法人嘉义长庚纪念医院 量化靶基因的突变型等位基因负担的方法
CN112424382A (zh) * 2019-04-05 2021-02-26 Illumina公司 Hla多样性的定量评分
CN112424382B (zh) * 2019-04-05 2024-05-28 Illumina公司 Hla多样性的定量评分
US12031181B2 (en) 2019-04-05 2024-07-09 Illumina, Inc. Quantitative score of HLA diversity
CN114245874A (zh) * 2019-05-24 2022-03-25 艾迪菲斯健康有限公司 用于癌症免疫疗法的精准医学方法
CN111088349A (zh) * 2020-02-14 2020-05-01 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
CN115667550A (zh) * 2020-03-23 2023-01-31 皇家飞利浦有限公司 基于免疫检查点基因对前列腺癌对象的放疗反应的预测

Also Published As

Publication number Publication date
BR112016015399A2 (pt) 2017-10-24
US20160326597A1 (en) 2016-11-10
RU2707530C2 (ru) 2019-11-27
SG10201805674YA (en) 2018-08-30
RU2016131207A3 (https=) 2018-06-22
CL2016001708A1 (es) 2017-03-17
MX2016008771A (es) 2016-12-20
SG11201605432RA (en) 2016-07-28
JP2017504324A (ja) 2017-02-09
EP3090066A4 (en) 2017-08-30
PE20161344A1 (es) 2016-12-23
WO2015103037A2 (en) 2015-07-09
RU2016131207A (ru) 2018-02-07
WO2015103037A3 (en) 2015-11-05
CA2935214A1 (en) 2015-07-09
EP3090066A2 (en) 2016-11-09
KR20160102314A (ko) 2016-08-29
AU2014374020A1 (en) 2016-08-18
PH12016501329A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
RU2707530C2 (ru) Детерминанты ответа раковой опухоли на иммунотерапию
US12485162B2 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
Bassani-Sternberg et al. A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma—a proof of antigen discovery feasibility in three patients
AU2018338441B2 (en) Tumor mutational load and checkpoint immunotherapy
EP4600375A2 (en) Systems and methods for sequencing t cell receptors and uses thereof
US20210147942A1 (en) Method to assess suitability for cancer immunotherapy
Wang et al. Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T-cell responses in glioblastoma
HK40098129A (en) Tumor mutational load and checkpoint immunotherapy
Sharad et al. Identification of Therapeutic Targets and Novel Biomarkers in Prostate Cancer
Merghoub et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Kostine Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients?
HK40032690A (en) Tumor mutational load and checkpoint immunotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161123

RJ01 Rejection of invention patent application after publication